SKYENasdaqPharmaceutical PreparationsFiscal year ends December 31
Skye Bioscience, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.53−0.02 (-1.29%)
Close on Oct 19, 2026
- Market cap
- $60.73M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$9.51 (−86.14%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $60.73M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -63.90%
Fundamentals
- Net income
- -$50.49M
- EPS, diluted
- -$1.27
- Free cash flow
- -$38.81M
- Book value per share
- -$0.01
- Diluted shares
- 40M
Fourteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Operating income
-$51.90M
Net income
-$50.49M
EPS, diluted
-$1.27
Free cash flow
-$38.81M
Reported periodTrailing twelve months